14804-61-6

Basic information

• Product Name: 1-(1-bromoethyl)-4-chlorobenzene
• Synonyms: 1-(1-bromoethyl)-4-chlorobenzene;Einecs 238-870-0
• CAS NO: 14804-61-6
• Molecular Formula: C₈H₈BrCl
• Molecular Weight: 219.50612
• EINECS: 238-870-0
• Mol File: 14804-61-6.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 236.6°Cat760mmHg
• Flash Point: 116.9°C
• Appearance: /
• Density: 1.481g/cm³
• Vapor Pressure: 0.0719mmHg at 25°C
• Refractive Index: 1.567
• CAS DataBase Reference: 1-(1-bromoethyl)-4-chlorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1-bromoethyl)-4-chlorobenzene(14804-61-6)
• EPA Substance Registry System: 1-(1-bromoethyl)-4-chlorobenzene(14804-61-6)

Safety Data

• Hazardous Substances Data: 14804-61-6(Hazardous Substances Data)

Usage

General Description

1-(1-bromoethyl)-4-chlorobenzene is a chemical compound with the molecular formula C8H8BrCl. It is a colorless liquid at room temperature and is commonly used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. It is also used as a solvent and in research applications. The compound is moderately toxic and is known to irritate the skin and eyes upon contact. It is typically stored and handled with proper safety precautions to prevent exposure and potential health hazards.

InChI:InChI=1/C8H8BrCl/c1-6(9)7-2-4-8(10)5-3-7/h2-6H,1H3

Upstream product

• 622-98-0 4-chloro(ethylbenzene) 
• 67-66-3 chloroform 
• 7726-95-6 bromine 
• 104-88-1 4-chlorobenzaldehyde 
• 1073-67-2 4-vinylbenzyl chloride 
• 89619-10-3 1-(1-bromovinyl)-4-chlorobenzene 
• 100-41-4 ethylbenzene 
• 3391-10-4 1-(p-chlorophenyl)ethyl alcohol 
• 99-91-2 para-chloroacetophenone 

Downstream Products

• 59771-09-4 Diethyl-<1-(4'-chlorphenyl)-ethyl)>-malonat 
• 29342-34-5 1-(4-chlorophenyl)-1-nitroethane 
• 938-95-4 2-(4-Chloro-phenyl)-propionic acid 
• 184879-37-6 3-(4-Chloro-phenyl)-2-(4-isopropyl-phenoxy)-2-methyl-butyric acid ethyl ester 
• 184879-34-3 3-(4-Chloro-phenyl)-2-(4-isopropyl-phenoxy)-butyric acid ethyl ester 
• 794535-32-3 (+/-)-{4-[1-(4-chlorophenyl)ethyl]-7-fluoro-5-(methanesulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl}acetic acid 
• 1066-37-1 trimethylbromogermane 
• 169059-34-1 (1-(4-chlorophenyl)ethyl)(phenyl)sulfane 
• 1066-44-0 trimethyltin bromide 
• 1126896-41-0 1-chloro-4-(4-phenylbut-3-yn-2-yl)benzene 

Relevant articles and documents

Pharmacological characterization of [3H]VUF11211, a novel radiolabeled small-molecule inverse agonist for the chemokine receptor CXCR3

Chemokine receptor CXCR3 has attracted much attention, as it is thought to be associated with a wide range of immunerelated diseases. As such, several small molecules with different chemical structures targeting CXCR3 have been discovered. Despite limited clinical success so far, these compounds serve as interesting tools for investigating receptor activation and antagonism. Accumulating evidence suggests that many of these compounds are allosteric modulators for CXCR3. One feature of allosteric ligands is that the magnitude of the mediated allosteric effect is dependent on the orthosteric probe that is used. Consequently, there is a risk for incorrect assessment of affinity for allosteric modulators with orthosteric radioligands, which has so far been the most applied approach for chemokine receptors. Therefore, we aimed to use a small-molecule allosteric ligand from the piperazinyl-piperidine class, also known as VUF11211 [(S)-5- chloro-6-(4-(1-(4-chlorobenzyl)piperidin-4-yl)-3-ethylpiperazin- 1-yl)-N-ethylnicotinamide]. VUF11211 acts as an inverse agonist at a constitutively active mutant of CXCR3. Radiolabeling of VUF11211 gave [3H]VUF11211, which in radioligand binding studies shows high affinity for CXCR3 (Kd 5 0.65 nM) and reasonably fast association (kon5 0.03 minute-1nM21) and dissociation kinetics (koff 5 0.02 minute21). The application of the [3H]VUF11211 to assess CXCR3 pharmacology was validated with diverse classes of CXCR3 compounds, including both antagonists and agonists, as well as VUF11211 analogs. Interestingly, VUF11211 seems to bind to a different population of CXCR3 conformations compared with the CXCR3 agonists CXC chemokine ligand 11 (CXCL11), VUF11418 [1-((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)- N-((29-iodobiphenyl-4-yl)methyl)-N,N-dimethylmethanaminium Iodide], and VUF10661 [N-(6- Amino-1-(2,2-diphenylethylamino)- 1-oxohexan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4- Tetrahydroisoquinoline- 3-carboxamide]. These findings, taken together, indicate that this allosteric inverse agonist radioligand for CXCR3 may facilitate the discovery, characterization, and optimization of allosteric modulators for the chemokine receptor CXCR3.

SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES

A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3′-indoline]-2′,5(3H)-dione analogues, the use thereof and the preparation thereof.

SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE

Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the γ-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.